NCT03806387View on ClinicalTrials.gov

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

CompletedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

July 30, 2020

Study Completion Date

June 30, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

Alemtuzumab

Alemtuzumab will be given two times, separated by 1 year.

Trial Locations (1)

8000

Aarhus University, Health, Section for Sport Science, Aarhus

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Aarhus

OTHER

NCT03806387 - Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment | Biotech Hunter | Biotech Hunter